Combination of breast cancer prevention with tissue-targeted hormone replacement therapy

Breast Cancer: Prognosis, Treatment, and Prevention

Volumn , Issue , 2008, Pages 201-252

  Labrie, Fernand ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868204294     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (337)

1. Abraham GE. Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle. J Clin Endocrinol Metab 1974; 39:340-346.
2. 5 steroids of the human adrenal gland. Mol Cell Endocrinol 1985; 41:1-17.
3. Adams J, Garcia M, Rochefort H. Estrogenic effects of physiological concentrations of 5-androstene-3-beta,17 beta-diol and its metabolism in MCF7 human breast cancer cells. Cancer Res 1981; 41:4720-4726.
4. Akaza H, Homma Y, Usami M, Hirao Y, Tsushima T, Okada K, Yokoyama M, Ohashi Y, Aso Y. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int 2006; 98(3):573-579.
5. Archer DF, Furst K, Tipping D, Dain MP, Vandepol C. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 1999; 94(4):498-503.
6. Arnst C. Why did prostate cancer death rates fall? Bus Week 2003; 3853:92.
7. Asselin J, Kelly PA, Caron MG, Labrie F. Control of hormone receptor levels and growth of 7,12-dimethylbenz(a)anthracene-induced mammary tumors by estrogens, progesterone and prolactin. Endocrinology 1977; 101:666-671.
8. Asselin J, Labrie F. Effects of estradiol and prolactin on steroid receptor levels in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and uterus in the rat. J Steroid Biochem 1978; 9:1079-1082.
9. Baselga J, Llombart-Cussac A, Bellet M, Guillem-Porta V, Enas N, Krejcy K, Carrasco E, Kayitalire L, Kuta M, Lluch A, Vodvarka P, Kerbrat P, Namer M, Petruzelka L. Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Ann Oncol 2003; 14(9):1383-1390.
10. Baulieu EE, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B, Faucounau V, Girard L, Hervy MP, Latour F, Leaud MC, Mokrane A, Pitti-Ferrandi H, Trivalle C, de Lacharriere O, Nouveau S, Rakoto-Arison B, Souberbielle JC, Raison J, Le Bouc Y, Raynaud A, Girerd X, Forette F. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A 2000; 97(8):4279-4284.
11. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359(9324):2131-2139.
12. Beattie MS, Costantino JP, Cummings SR, Wickerham DL, Vogel VG, Dowsett M, Folkerd EJ, Willett WC, Wolmark N, Hankinson SE. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). J Natl Cancer Inst 2006; 98(2):110-115.
13. Bélanger B, Béilanger A, Labrie F, Dupont A, Cusan L, Monfette G. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem 1989; 32:695-698.
14. Belanger A, Brochu M, Cliche J. Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer. J Clin Endocrinol Metab 1986; 62:812-815.
15. Belanger A, Candas B, Dupont A, Cusan L, Diamond P, Gomez JL, Labrie F. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab 1994; 79:1086-1090.
16. Bélanger A, Pelletier G, Labrie F, Barbier O, Chouinard S. Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol Metab 2003; 14:473-479.
17. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365(9470):1543-1551.
18. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 2000; 356(9233):881-887.
19. Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajno R, Pisani P, Panico S, Secreto G. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996; 88(5):291-296.
20. Bieche I, Parfait B, Tozlu S, Lidereau R, Vidaud M. Quantitation of androgen receptor gene expression in sporadic breast tumors by real-time RT-PCR: evidence that MYC is an AR-regulated gene. Carcinogenesis 2001; 22(9):1521-1526.
21. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, Tilley WD. Androgens induce divergent pro-liferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 1995; 52(5):459-167.
22. Birrell SN, Hall RE, Tilley WD. Role of the androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia 1998; 3(1):95-103.
23. Boccuzzi G, Aragno M, Brignardello E, Tamagno E, Conti G, Di Monaco M, Racca S, Danni O, Di Carlo F. Opposite effects of dehydroepiandrosterone on the growth of 7, 12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. Anticancer Res 1992a; 12:1479-1484.
24. Boccuzzi G, Brignardello E, di Monaco M, Forte C, Leonardi L, Pizzini A. Influence of dehydroepiandrosterone and 5-en-androstene-3 beta, 17 beta-diol on the growth of MCF-7 human breast cancer cells induced by 17 beta-estradiol. Anticancer Res 1992b; 12(3):799-803.
25. Boccuzzi G, Di Monaco M, Brignardello E, Leonardi L, Gatto V, Pizzini A, Gallo M. Dehydroepiandrosterone antiestrogenic action through androgen receptor in MCF-7 human breast cancer cell line. Anticancer Res 1993; 13(6A):2267-2272.
26. Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18(22):3748-3757.
27. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003; 18(11):937-947.
28. Brys M, Wojcik M, Romanowicz-Makowska H, Krajewska WM. Androgen receptor status in female breast cancer: RT-PCR and Western blot studies. J Cancer Res Clin Oncol 2002; 128(2):85-90.
29. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389(6652):753-758.
30. Bulbrook RD, Hayward JL, Spicer CC. Relation between urinary androgen and corticoid excretion and subsequent breast cancer. Lancet 1971; 2:395-398.
31. Burak WE, Quinn AL Jr., Farrar WB, Brueggemeier RW. Androgens influence estrogen-induced responses in human breast carcinoma cells through cytochrome P450 aromatase. Breast Cancer Res Treat 1997; 44(1):57-64.
32. Burger HG. Should testosterone be added to estrogen-progestin therapy for breast protection? Menopause 2007; 14(2): 159-162.
33. Burgess HE, Shousha S. An immunohistochemical study of the long-term effects of androgen administration on female-to-male transsexual breast: a comparison with normal female breast and male breast showing gynaecomastia. J Pathol 1993; 170(1):37-43.
34. Buzdar A, O'Shaughnessy JA, Booser DJ, Pippen JE, Jones SE Jr., Munster PN, Peterson P, Melemed AS, Winer E, Hudis C. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 2003; 21(6): 1007-1014.
35. Calhoun KE, Pommier RF, Muller P, Fletcher WS, Toth-Fejel S. Dehydroepiandrosterone sulfate causes proliferation of estrogen receptor-positive breast cancer cells despite treatment with fulvestrant. Arch Surg 2003; 138(8):879-883.
36. Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, Ross SD. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997; 49:71-78.
37. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1999; 130(4 pt 1):270-277.
38. Chalbos D, Haagensen DE, Parish T, Rochefort H. Identification and androgen regulation of two proteins released by T47D human breast cancer cells. Cancer Res 1987; 47:2787-2792.
39. Cheng Y, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) on an enzymatic reaction. Biochem Pharmacol 1973; 22:3099-3108.
40. Christiansen C, Christensen MS, Larsen NE, Transbol IB. Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose-response relationships in early postmenopausal women. J Clin Endocrinol Metab 1982; 55:1124-1130.
41. Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001; 53(1):25-71.
42. Clemens JA, Bennett DR, Black LJ, Jones CD. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 1983; 32(25):2869-2875.
43. Coleman RE, Banks LM, Hall E, Price D, Girgis S, Bliss JM, Coombes RC. Intergroup Exemestane Study: one year results of the bone sub-protocol. Breast Cancer Res Treat 2004; 88(1):S35.
44. Conde I, Alfaro JM, Fraile B, Ruiz A, Paniagua R, Arenas MI. DAX-1 expression in human breast cancer: comparison with estrogen receptors ER-alpha, ER-beta and androgen receptor status. Breast Cancer Res 2004; 6(3):R140-R148.
45. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350(11):1081-1092.
46. Cooperative Breast Cancer Group. Testosterone propionate therapy of breast cancer. J Am Med Ass 1964; 188: 1069-1072.
47. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003; 95(13):981-999.
48. Costlow ME, Buschow RA, McGuire WL. Prolactin receptors and androgen-induced regression of 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma. Cancer Res 1976; 36(9 pt 1):3324-3329.
49. Couillard S, Labrie C, Belanger A, Candas B, Pouliot F, Labrie F. Effect of dehydroepiandrosterone and the antiestrogen EM-800 on the growth of human ZR-75-1 breast cancer xenografts. J Natl Cancer Inst 1998; 90:772-778.
50. Couture P, Thériault C, Simard J, Labrie F. Androgen receptor-mediated stimulation of 17b-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Endocrinology 1993; 132:179-185.
51. Cowie AT, Folley SJ. The mammary gland and lactation. In: Young WC, ed. Sex and Internal Secretion. Baltimore: Williams and Wilkins, 1961:590-641.
52. Cox DG, Blanche H, Pearce CL, Calle EE, Colditz GA, Pike MC, Albanes D, Allen NE, Amiano P, Berglund G, Boeing H, Buring J, Burtt N, Canzian F, Chanock S, Clavel-Chapelon F, Feigelson HS, Freedman M, Haiman CA, Hankinson SE, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel L, Kraft P, Lemarchand L, Lund E, Palli D, Peeters PH, Riboli E, Stram DO, Thun M, Tjonneland A, Trichopoulos D, Yeager M. A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Breast Cancer Res 2006; 8(5):R54.
53. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321(7):419-124.
54. Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 2002; 287(2): 216-220.
55. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281(23):2189-2197.
56. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet 1985; 2(8449):282.
57. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360(9336): 817-824.
58. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361(9354):296-300.
59. Dao TL, Chistakos SS, Varela R. Biochemical characterization of carcinogen-induced mammary hyperplastic aveolar nodule and tumor in the rat. Cancer Res 1975; 35(5):1128-1134.
60. Dauvois S, Geng CS, Lévesque C, Mérand Y, Labrie F. Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Res 1991; 51:3131-3135.
61. Dauvois S, Li S, Martel C, Labrie F. Inhibitory effect of androgens on DMBA-induced mammary carcinoma in the rat. Breast Cancer Res Treat 1989; 14:299-306.
62. Davidson NE, Lippman ME. The role of estrogens in growth regulation of breast cancer. Crit Rev Oncog 1989; 1:89-111.
63. de Launoit Y, Dauvois S, Dufour M, Simard J, Labrie F. Inhibition of cell cycle kinetics and proliferation by the androgen 5 alpha-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-[16' alpha-chloro-3',17 beta-dihydroxy-estra-1',3',5'-(10')triene-7' alpha-yl] undecanamide in human breast cancer ZR-75-1 cells. Cancer Res 1991a; 51(11):2797-2802.
64. de Launoit Y, Veilleux R, Dufour M, Simard J, Labrie F. Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res 1991b; 51(19):5165-5170.
65. Denis L, Carnelro de Moura J, Bono A, Sylvester R, Whelan P, Newling D, Depauw M. Goserelin acetate and flutamide vs. bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 1993; 42:119-129.
66. Diamond P, Cusan L, Gomez JL, Beilanger A, Labrie F. Metabolic effects of 12-month percutaneous DHEA replacement therapy in postmenopausal women. J Endocrinol 1996; 150:S43-S50.
67. Dimitrakakis C, Jones RA, Liu A, Bondy CA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause 2004; 11(5):531-535.
68. Dimitrakakis C, Zhou J, Wang J, Belanger A, LaBrie F, Cheng C, Powell D, Bondy C. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003; 10(4):292-298.
69. Dorgan JF, Longcope C, Stephenson HE Jr., Falk RT, Miller R, Franz C, Kahle L, Campbell WS, Tangrea JA, Schatzkin A. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996; 5(7):533-539.
70. Dorgan JF, Stanczyk FZ, Longcope C, Stephenson HE Jr., Chang L, Miller R, Franz C, Falk RT, Kahle L. Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 beta, 17 beta-diol to risk of breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 1997; 6(3):177-181.
71. Dowsett M, Cuzick J, Howell A, Jackson I. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. Br J Cancer 2001; 85(3): 317-324.
72. Dufort I, Rheault P, Huang XF, Soucy P, Luu-The V. Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Endocrinology 1999; 140(2):568-574.
73. Dumont M, Dauvois S, Simard J, Garcia T, Schachter B, Labrie F. Antagonism between estrogens and androgens on GCDFP-15 gene expression in ZR-75-1 cells and correlation between GCDFP-15 and estrogen as well as progesterone receptor expression in human breast cancer. J Steroid Biochem 1989; 34:397-402.
74. EBCTCG. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 351(9114):1451-1467.
75. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365(9472):1687-1717.
76. Edery M, Goussard J, Dehennin L, Scholler R, Reiffsteck J, Drosdowsky MA. Endogenous oestradiol-17beta concentration in breast tumours determined by mass fragmentography and by radioimmunoassay: relationship to receptor content. Eur J Cancer 1981; 17(1):115-120.
77. Egawa M, Misaki T, Imao T, Yokoyama O, Fuse H, Suzuki K, Namiki M. Retrospective study on stage B prostate cancer in the Hokuriku District, Japan. Int J Urol 2004; 11(5): 304-309.
78. Ekena K, Katzenellenbogen JA, Katzenellenbogen BS. Determinants of ligand specificity of estrogen receptor-alpha: estrogen versus androgen discrimination. J Biol Chem 1998; 273(2):693-699.
79. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk? J Clin Oncol 2006; 24 (12):1823-1830.
80. Engel LW, Young NA, Tralka TS, Lippman ME, O'Brien SJ, Joyce MJ. Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res 1978; 38(10):3352-3364.
81. Fels E. Treatment of breast cancer with testosterone propionate. A preliminary report. J Clin Endocrinol 1944; 4:121-125.
82. Fisher B, Costantino JP, Lawrence Wickerham D, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998; 90:1371-1388.
83. Fisher B, Costantino C, Redmond ER, Fisher D, Wickerham L, Cronin WM, NSABP Contributors. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86:527-537.
84. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97(22):1652-1662.
85. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AHG, Feldman MI, Farrar W, Evans J, Lickley HL. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen-positive tumors. J Natl Cancer Inst 1996; 88:1529-1542.
86. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93(9):684-690.
87. Fisher B, Powles TJ, Pritchard KJ. Tamoxifen for the prevention of breast cancer. Eur J Cancer 2000; 36(2):142-150.
88. Fishman J, Nisselbaum JS, Menendez-Botet CJ, Schwartz MK. Estrone and estradiol content in human breast tumors: relationship to estradiol receptors. J Steroid Biochem 1977; 8(8):893-896.
89. Forsyth IA, Jones EA. Organ culture of mammary gland and placenta in the study of hormone action and placental secretion. In: Balls M, Monnickendam MA, eds. Organ Culture in Biomedical Research. England, UK: Cambridge University Press, 1976:201-221.
90. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 2004; 64(4): 1522-1533.
91. Gammon MD, Thompson WD. Polycystic ovaries and the risk of breast cancer. Am J Epidemiol 1991; 134(8):818-824.
92. Garcia M, Rochefort H. Androgen effects mediated by estrogen receptor in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. Cancer Res 1978; 38:3922-3929.
93. Gatto V, Aragno M, Gallo M, Tamagno E, Martini A, Di Monaco M, Brignardello E, Boccuzzi G. Dehydroepiandrosterone inhibits the growth of DMBA-induced rat mammary carcinoma via the androgen receptor. Oncol Rep 1998; 5(1):241-243.
94. Gauthier S, Caron B, Cloutier J, Dory YL, Favre A, Larouche D, Mailhot J, Ouellet C, Schwerdtfeger A, Leblanc G, Martel C, Simard J, Merand Y, Belanger A, Labrie C, Labrie F. (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen. J Med Chem 1997; 40:2117-2122.
95. Gayosso V, Montano LF, Lopez-Marure R. DHEA-induced antiproliferative effect in MCF-7 cells is androgen- and estrogen receptor-independent. Cancer J 2006; 12(2): 160-165.
96. Geisler J. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 2003; 86(3-5):245-253.
97. Geisler J, AnkerG, Dowsett M, Lonning PE. Letrozole supresses plasma estrogen levels in breast cancer patients more completely than anastrazole. Proc Am Assoc Clin Oncol 2000; 19:A102.
98. Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjorn B, Dowsett M, Einstein Lonning P. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001; 7(5):1230-1236.
99. Gelfand MM. It might be wise to consider adding androgen to the estrogen or estrogen-progestin regimens in the appropriate patients. Menopause 2004; 11(5):505-507.
100. Geriani RL. Fetal mammary gland differentiation in vitro in response to hormones I. Morphological findings. Dev Biol 1970; 21:506-529.
101. Giguere Y, Dewailly E, Brisson J, Ayotte P, Laflamme N, Demers A, Forest VI, Dodin S, Robert J, Rousseau F. Short polyglutamine tracts in the androgen receptor are protective against breast cancer in the general population. Cancer Res 2001; 61(15):5869-5874.
102. Gordan GS. Anabolic-androgenic steroids. In: Eichler O, Heffter A, Heubner W, eds. Handbook of Experimental Pharmacology. Berlin, New York: Springer-Verlag, 1976:499-513.
103. Gordan GS, Halden A, Horn Y, Fuery JJ, Parsons RJ, Walter RM. Calusterone (7b,17a-dimethyltestosterone) as primary and secondary therapy of advanced breast cancer. Oncology 1973; 28(2):138-146.
104. Gordon GB, Newitt JA, Shantz LM, Weng DE, Talalay P. Inhibition of the conversion of 3T3 fibroblast clones to adipocytes by dehydroepiandrosterone and related anticar-cinogenic steroids. Cancer Res 1986; 46(7):3389-3395.
105. Goss P. Anti-aromatase agents in the treatment and prevention of breast cancer. Cancer Control 2002; 9(suppl 2):2-8.
106. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 19:1793-1802.
107. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988; 48:812-815.
108. Griffiths K, Jones D, Cameron EHD, Gleave EN, Forrest APM. Transformation of steroids by mammary cancer tissue. In: Dao TL, ed. Estrogen Target Tissues and Neoplasia. Chicago: University of Chicago Press, 1972:151-162.
109. Grino PB, Griffin JE, Cushard WG Jr., Wilson JD. A mutation of the androgen receptor associated with partial androgen resistance, familial gynecomastia, and fertility. J Clin Endocrinol Metab 1988; 66(4):754-761.
110. Gronemeyer H, Benhamou B, Berry M, Bocquel MT, Gofflo D, Garcia T, Lerouge T, Metzger D, Meyer ME, Tora L, Vergezac A, Chambon P. Mechanisms of antihormone action. J Steroid Biochem Mol Biol 1992; 41:217-221.
111. Gutman M, Couillard S, Labrie F, Candas B, Labrie C. Effect of treatment sequence with radiotherapy and the antiestrogen EM-800 on the growth of ZR-75-1 human mammary carcinoma in nude mice. Int J Cancer 2003; 103(2):268-276.
112. Gutman M, Couillard S, Roy J, Labrie F, Candas B, Labrie C. Comparison of the effects of EM-652 (SCH 57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. Int J Cancer 2002; 99:273-278.
113. Haiman CA, Brown M, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Kantoff PW, Hunter DJ. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses Health Study. Cancer Res 2002; 62(4): 1045-1049.
114. Hall M, Bates S, Peters G. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 1995; 11:1581-1588.
115. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998; 90(17):1292-1299.
116. Helzlsouer KJ, Gordon GB, Alberg AJ, Bush TL, Comstock GW. Relationship of prediagnostic serum levels of dehydroe-piandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Res 1992; 52(1):1-1.
117. Hofling M, Hirschberg AL, Skoog L, Tani E, Hagerstrom T, von Schoultz B. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause 2007; 14(2):183-190.
118. Horwitz KB, Zava DT, Thilager AK, Jensen ET, McGuire WL. Steroid receptor analyses of nonhuman breast cancer cell lines. Cancer Res 1978; 38:2434-2439.
119. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmeno-pausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004; 22(9):1605-1613.
120. Howell A, Robertson J, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progression after prior endocrine treatment. J Clin Oncol 2002; 20(16):3396-3403.
121. Huggins C, Briziarelli G, Sutton HJ. Rapid induction of mammary carcinoma in the rat and the influence of hormone on the tumors. J Exp Med 1959; 109:25-42.
122. Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, Tschetter LK, Long HJ, Gerstner JG, Windschitl HE, Levitt R, Pfeifle DM. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. A phase II study. Cancer 1991; 67:886-891.
123. Isaksson E, von Schoultz E, Odlind V, Soderqvist G, Csemiczky G, Carlstrom K, Skoog L, von Schoultz B. Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 2001; 65(2):163-169.
124. Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 1993; 170(1):31-35.
125. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995; 13(2):513-529.
126. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366(9484):455-462.
127. Jayo MJ, Register TC, Hughes CL, Blas-Machado U, Sulistiawati E, Borgerink H, Johnson CS. Effects of an oral contraceptive combination with or without androgen on mammary tissues: a study in rats. J Soc Gynecol Investig 2000; 7(4):257-265.
128. Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 2005; 65(12):5439-5444.
129. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M. Cancer Statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
130. Johannessen DC, Engan T, Di Salle E, Zurlo MG, Paolini J, Ornati G, Piscitelli G, Kvinnsland S, Lonning PE. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997; 3(7):1101-1108.
131. Johnston SR. 2005 Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer-have they lost their way? Breast Cancer Res 7(3):119-130.
132. Jones J, Vukelja S, Cantrell J. A planned comparison of menopausal symptoms during year 1 in patients receiving either examestane or tamoxifene in a double-blind adjuvant hormonal study. Breast Cancer Res Treat 2003; 82:S31.
133. Jordan VC. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinoma. Eur J Cancer 1976; 12:419-124.
134. Jordan VC. Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy. Rev Endocr Relat Cancer 1978; suppl 1:49-55.
135. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, Bingham S, Boeing H, Bueno de Mesquita HB, Chang-Claude J, Clavel-Chapelon F, Fournier A, van Gils CH, Gonzalez CA, Gurrea AB, Critselis E, Khaw KT, Krogh V, Lahmann PH, Nagel G, Olsen A, Onland-Moret NC, Overvad K, Palli D, Panico S, Peeters P, Quiros JR, Roddam A, Thiebaut A, Tjonneland A, Chirlaque MD, Trichopoulou A, Trichopoulos D, Tumino R, Vineis P, Norat T, Ferrari P, Slimani N, Riboli E. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005; 97(10): 755-765.
136. Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE. A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev 2000; 9(6): 575-579.
137. Kasid A, Strobl JS, Huff K, Greene GL, Lippman ME. A novel nuclear form of estradiol receptor in MCF-7 human breast cancer cells. Science 1984; 225(4667):1162-1165.
138. Kawamura I, Mizota T, Kondo N, Shimomura K, Kohsaka M. Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats. Jpn J Pharmacol 1991; 57:215-224.
139. Kelly PA, Tsushima T, Shiu RP, Friesen HG. Lactogenic and growth hormone-like activities in pregnancy determined by radioreceptor assays. Endocrinology 1976; 99(3):765-774.
140. Kennedy BJ. Fluxymesterone therapy in treatment of advanced breast cancer. N Engl J Med 1958; 259:673-675.
141. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94(8):606-616.
142. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001; 2(3):133-140.
143. Key TJ, Wang DY, Brown JB, Hermon C, Allen DS, Moore JW, Bulbrook RD, Fentiman IS, Pike MC. A prospective study of urinary oestrogen excretion and breast cancer risk. Br J Cancer 1996; 73(12):1615-1619.
144. Kimura N, Mizokami A, Oonuma T, Sasano H, Nagura H. Immunocytochemical localization of androgen receptor with polyclonal antibody in paraffin-embedded human tissues. J Histochem Cytochem 1993; 41:671-678.
145. King RJB, Gordon J, Helfenstein JE. The metabolism of testosterone by tissue from normal and neoplastic rat breast. J Endocrinol 1964; 29:103-110.
146. King RJB, Panattoni M, Gordon J, Baker R. The metabolism of steroids by tissue from normal and neoplastic rat breast. J Endocrinol 1965; 33:127-132.
147. Klotz L. Combined androgen blockade in prostate cancer: meta-analyses and associated issues. BJU Int 2001; 87(9): 806-813.
148. Korkia P, Stimson GV. Indications of prevalence, practice and effects of anabolic steroid use in Great Britain. Int J Sports Med 1997; 18(7):557-562.
149. Kratochwil K. Development and loss of androgen responsiveness in the embryonic rudiment of the mouse mammary gland. Dev Biol 1977; 61(2):358-365.
150. Kreitmann B, Bayard F. Androgen interaction with the oestrogen receptor in human tissues. J Steroid Biochem 1979; 11:1589-1595.
151. Kushnir MM, Rockwood AL, Roberts WL, Pattison EG, Bunker AM, Fitzgerald RL, Meikle AW. Performance characteristics of a novel tandem mass spectrometry assay for serum testosterone. Clin Chem 2006; 52(1):120-128.
152. Labrie F. Intracrinology. Mol Cell Endocrinol 1991; 78: C113-C118.
153. Labrie F. Future perspectives of SERMs used alone and in combination with DHEA. Endocr Relat Cancer 2006; 13(2): 335-355.
154. Labrie F. Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy. Nat Clin Pract Endocrinol Metab 2007; 3(8):584-593.
155. Labrie F, Auclair C, Cusan L, Kelly PA, Pelletier G, Ferland L. Inhibitory effects of LHRH and its agonists on testicular gonadotropin receptors and spermatogenesis in the rat. Int J Androl Suppl 1978; 2:303-318.
156. Labrie F, Belanger A, Belanger P, Bérubé R, Martel C, Cusan L, Gomez JL, Candas B, Castiel I, Chaussade V, Deloche C, Leclaire J. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Ster Biochem Mol Biol 2006a; 99:182-188.
157. Labrie F, Belanger A, Belanger P, Berube R, Martel C, Cusan L, Gomez J, Candas B, Chaussade V, Castiel I, Deloche C, Leclaire J. Metabolism of DHEA in postmenopausal women following percutaneous administration. J Steroid Biochem Mol Biol 2007; 103(2):178-188.
158. Labrie F, Belanger A, Candas B, Cusan L, Gomez JL, Labrie C, Luu-The V, Simard J. GnRH agonists in the treatment of prostate cancer. Endocrine Reviews 2005a; 26(3):361-379.
159. Labrie F, Belanger A, Cusan L, Candas B. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab 1997a; 82(8):2403-2409.
160. Labrie F, Belanger A, Cusan L, Gomez JL, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol. Metab 1997b; 82:2396-2402.
161. Labrie F, Belanger A, Dupont A, Luu-The V, Simard J, Labrie C. Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 1993; 16:475-192.
162. Labrie C, Belanger A, Labrie F. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 1988; 123:1412-1417.
163. Labrie F, Belanger A, Simard J, Luu-The V, Labrie C. DHEA and peripheral androgen and estrogen formation: Intracrinology. Ann N Y Acad Sci 1995a; 774:16-28.
164. Labrie F, Candas B, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996b; 47:212-217.
165. Labrie F, Candas B, Gomez JL, Cusan L. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology 2002; 60(1): 115-119.
166. Labrie F, Champagne P, Labrie C, Belanger A, Roy J, Laverdière J, Deschênes L, Provencher L, Potvin M, Drolet Y, Pollak M, Panasci L, L'Espérance B, Dufresne J, Latreille J, Robert J, Samson B, Jolivet J, Yelle L, Cusan L, Diamond P, Candas B. Activity and safety of the orally active pure antiestrogen EM-800 (SCH 57050) in Tamoxifen-resistant breast cancer. J Clin Oncol 2004a; 22(5):864-871.
167. Labrie F, Diamond P, Cusan L, Gomez JL, Belanger A. Effect of 12-month DHEA replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997c; 82:3498-3505.
168. Labrie F, Dupont A, Belanger A. Complete androgen blockade for the treatment of prostate cancer. In: de Vita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia: J.B. Lippincott, 1985: 193-217.
169. Labrie F, Dupont A, Belanger A, Cusan L, Lacourcière Y, Monfette G, Laberge JG, Emond J, Fazekas AT, Raynaud JP, Husson JM. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 1982; 5:267-275.
170. Labrie Y, Durocher F, Lachance Y, Turgeon C, Simard J, Labrie C, Labrie F. The human type II 17b-hydroxysteroid dehydrogenase gene encodes two alternatively-spliced messenger RNA species. DNA Cell Biol 1995b; 14:849-861.
171. Labrie F, El-Alfy M, Berger L, Labrie C, Martel C, Belanger A, Candas B, Pelletier G. The combination of a novel SERM with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women's health? Endocrinology 2003a; 144(11):4700-4706.
172. Labrie C, Flamand M, Belanger A, Labrie F. High bioavailability of DHEA administered percutaneously in the rat. J Endocrinol 1996a; 150:S107-S118.
173. Labrie F, Labrie C, Belanger A, Simard J. Third and fourth generation SERMs. In: Manni A, Verderame M, eds. Selective Estrogen Receptor Modulators: Research and Clinical Applications. Totowa, NJ: Humana Press, 2002:167-187.
174. Labrie F, Labrie C, Belanger A, Simard J, Giguère V, Tremblay A, Tremblay G. EM-652 (SCH 57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J Steroid Biochem Mol Biol 2001a; 79:213-225.
175. Labrie F, Labrie C, Simard J, Belanger A. New generation selective estrogen receptor modulators (SERMS). Steroides sexuels: Le point sur l'action des estrogènes et des progestatifs, Montpellier, France, 2004b.
176. Labrie F, Li S, Labrie C, Levesque C, Merand Y. Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12 dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Breast Cancer Res Treat 1995c; 33:237-244.
177. Labrie F, Luu-The V, Belanger A, Lin S-X, Simard J, Labrie C. Is DHEA a hormone? Starling Review. J Endocrinol 2005b; 187:169-196.
178. Labrie F, Luu-The V, Labrie C, Bélanger A, Simard J, Lin S-X, Pelletier G. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003b; 24(2):152-182.
179. Labrie F, Luu-The V, Labrie C, Simard J. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol 2001b; 22(3):185-212.
180. Labrie F, Luu-The V, Lin SX, Labrie C, Simard J, Breton R, Belanger A. The key role of 17b-HSDs in sex steroid biology. Steroids 1997d; 62:148-158.
181. Labrie F, Luu-The V, Lin SX, Simard J, Labrie C, El-Alfy M, Pelletier G, Belanger A. Intracrinology: role of the family of 17b-hydroxysteroid dehydrogenases in human physiology and disease. J Mol Endocrinol 2000; 25(1):1-16.
182. Labrie F, Luu-The V, Martel C, Chernomoretz A, Calvo E, Morissette J, Labrie C. DHEA is an anabolic steroid like testosterone and THG. J Steroid Biochem Mol Biol 2006b; 100(103):52-58.
183. Labrie C, Martel C, Dufour JM, Levesque C, Merand Y, Labrie F. Novel compounds inhibit estrogen formation and action. Cancer Res 1992a; 52:610-615.
184. Labrie F, Poulin R, Simard J, Luu-The V, Labrie C, Belanger A. Androgens, DHEA and breast cancer. In: Gelfand T, ed. Androgens and Reproductive Aging. Oxsfordshire UK: Taylor and Francis, 2006c:113-135.
185. Labrie F, Simard J, Labrie C, Belanger A. EM-652 (SCH 57068), a pure SERM in the mammary gland and endometrium. References en Gynécologie Obstétrique 2001c; 8:331-336.
186. Labrie F, Simard J, Luu-The V, Belanger A, Pelletier G. Structure, function and tissue-specific gene expression of 3b-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues. J Steroid Biochem Mol Biol 1992b; 43:805-826.
187. Labrie F, Simard J, Luu-The V, Belanger A, Pelletier G, Morel Y, Mebarki F, Sanchez R, Durocher F, Turgeon C, Labrie Y, Rheaume E, Labrie C, Lachance Y. The 3b-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3b-HSD congenital deficiency. In: Hansson V, Levy FO, Tasken K, eds. Signal Transduction in Testicular Cells. Ernst Schering Research Foundation Workshop. Berlin, Heidelberg, New York: Springer-Verlag, 1996c:185-218.
188. Labrie F, Simard J, Luu-The V, Pelletier G, Belanger A, Lachance Y, Zhao HF, Labrie C, Breton N, de Launoit Y, Dumont M, Dupont E, Rheaume E, Martel C, Couet J, Trudel C. Structure and tissue-specific expression of 3b-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissues. J Steroid Biochem Mol Biol 1992c; 41:421-435.
189. Labrie F, Simard J, Luu-The V, Pelletier G, Belghmi K, Belanger A. Structure, regulation and role of 3b-hydroxysteroid dehydrogenase, 17b-hydroxysteroid dehydrogenase and aromatase enzymes in formation of sex steroids in classical and peripheral intracrine tissues. In: Sheppard MC, Stewart PM, eds. Hormone, Enzymes and Receptors. London, UK: Baillière's Clinical Endocrinology and Metabolism, Baillière Tindall, 1994:451-474.
190. Labrie C, Simard J, Zhao HF, Belanger A, Pelletier G, Labrie F. Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 1989; 124:2745-2754.
191. Labrie F, Sugimoto Y, Luu-The V, Simard J, Lachance Y, Bachvarov D, Leblanc G, Durocher F, Paquet N. Structure of human type II 5 alpha-reductase gene. Endocrinology 1992d; 131(3):1571-1573.
192. Lacassagne A. Hormonal Pathogenesis of Adenocarcinoma of the breast. Am J Cancer 1936; 27(2):217-228.
193. Lacey JV, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002; 288: 334-341.
194. Lea OA, Kvinnsland S, Thorsen T. Improved measurement of androgen receptors in human breast cancer. Cancer Res 1989; 49(24 pt 1):7162-7167.
195. Leblanc M, Belanger MC, Julien P, Tchernof A, Labrie C, Bélanger A, Labrie F. Plasma lipoprotein profile in the male cynomolgus monkey under normal, hypogonadal and combined androgen blockade conditions. J Clin Endocrinol Metab 2004; 89:1849-1857.
196. Leblanc M, Labrie C, Belanger A, Candas B, Labrie F. Pharmacokinetics of oral dehydroepiandrosterone (DHEA) in the ovariectomised cynomolgus monkey. J Steroid Biochem Mol Biol 2002; 81:159-164.
197. Leblanc M, Labrie C, Belanger A, Candas B, Labrie F. Bioavailability and pharmacokinetics of dehydroepian-drosterone in the cynomolgus monkey. J Clin Endocrinol Metab 2003; 88(9):4293-4302.
198. Lemieux C, Gelinas Y, Lalonde J, Labrie F, Cianflone K, Deshaies Y. Hypolipidemic action of the SERM acolbifene is associated with decreased liver MTP and increased SR-BI and LDL receptors. J Lipid Res 2005; 46(6):1285-1294.
199. Lemieux C, Picard F, Labrie F, Richard D, Deshaies Y. The estrogen antagonist EM-652 and dehydroepiandrosterone prevent diet- and ovariectomy-induced obesity. Obes Res 2003; 11(3):477-490.
200. Levesque C, Merand Y, Dufour JM, Labrie C, Labrie F. Synthesis and biological activity of new halo-steroidal antiestrogens. J Med Chem 1991; 34(5):1624-1630.
201. Levi MS, Borne RF, Williamson JS. A review of cancer chemopreventive agents. Curr Med Chem 2001; 8(11): 1349-1362.
202. Li S, Yan X, Belanger A, Labrie F. Prevention by dehydroe-piandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat. Breast Cancer Res Treat 1993; 29:203-217.
203. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002; 287(20):2668-2676.
204. Lippman ME, Bolan G, Huff K. The effect of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 1976; 36:4610.
205. 5 adrenal steroids. Endocrinology 1990; 127:2757-2762.
206. Liu CH, Laughlin GA, Fischer UG, Yen SS. Marked attenuation of ultradian and circadian rhythms of dehydroepiandros-terone in postmenopausal women: evidence for a reduced 17,20-desmolase enzymatic activity. J Clin Endocrinol Metab 1990; 71(4):900-906.
207. Lobaccaro JM, Lumbroso S, Belon C, Galtier-Dereure F, Bringer J, Lesimple T, Namer M, Cutuli BF, Pujol H, Sultan C. Androgen receptor gene mutation in male breast cancer. Hum Mol Genet 1993; 2:1799-1802.
208. Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Goloubeva OG, Brodie AM. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst 2004; 96(6):456-465.
209. Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005; 23(22): 5126-5137.
210. Lu Q, Liu Y, Long BJ, Grigoryev D, Gimbel M, Brodie A. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat 1999; 57(2):183-192.
211. Luo S, Labrie C, Belanger A, Labrie F. Effect of dehydroepiandrosterone on bone mass, serum lipids, and dimethylbenz(a)anthracene-induced mammary carcinoma in the rat. Endocrinology 1997a; 138:3387-3394.
212. Luo S, Martel C, Gauthier S, Merand Y, Bélanger A, Labrie C, Labrie F. Long term inhibitory effects of a novel antiestrogen on the growth of ZR-75-1 and MCF-7 human breast cancer tumors in nude mice. Int J Cancer 1997b; 73:735-739.
213. Luo S, Martel C, Sourla A, Gauthier S, Merand Y, Belanger A, Labrie C, Labrie F. Comparative effects of 28-day treatment with the new antiestrogen EM-800 and tamoxifen on estrogen-sensitive parameters in the intact mouse. Int J Cancer 1997c; 73:381-391.
214. Luo S, Sourla A, Labrie C, Belanger A, Labrie F. Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(a) anthracene (DMBA)-induced mammary carcinoma in the rat. Endocrinology 1997d; 138:4435-4444.
215. Luu-The V. Analysis and characteristics of multiple types of human 17beta-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol 2001; 76(1-5):143-151.
216. Luu-The V, Dufort I, Paquet N, Reimnitz G, Labrie F. Structural characterization and expression of the human dehydroepiandrosterone sulfotransferase gene. DNA Cell Biol 1995a; 14:511-518.
217. Luu-The V, Zhang Y, Poirier D, Labrie F. Characteristics of human types 1, 2 and 3 17b-hydroxysteroid dehydrogenase activities: oxidation-reduction and inhibition. J Steroid Biochem Mol Biol 1995b; 55:581-587.
218. Lyons WR. Hormonal synergism in mammary growth. Proc R Soc Biol 1958; 149:303-325.
219. MacIndoe JH, Etre LA. An antiestrogenic action of androgens in human breast cancer cells. J Clin Endocrinol Metab 1981; 53(4):836-842.
220. Mady EA, Ramadan EE, Ossman AA. Sex steroid hormones in serum and tissue of benign and malignant breast tumor patients. Dis Markers 2000; 16(3-4):151-157.
221. Maggiolini M, Donze O, Jeannin E, Ando S, Picard D. Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor alpha. Cancer Res 1999; 59(19):4864-4869.
222. Martel C, Picard S, Richard V, Belanger A, Labrie C, Labrie F. Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J Steroid Biochem Mol Biol 2000; 74(1-2):45-56.
223. Martel C, Sourla A, Pelletier G, Labrie C, Fournier M, Picard S, Li S, Stojanovic M, Labrie F. Predominant androgenic component in the stimulatory effect of dehydroepiandros-terone on bone mineral density in the rat. J Endocrinol 1998; 157:433-442.
224. McGuire WL, Carbone PP, Sears ME, Escher GC. Estrogen receptors in human breast cancer: an overview. In: McGuire WL, Carbone PP, Vollmer EP, eds. Estrogen Receptors in Human Breast Cancer. New York: Raven Press, 1975:1-7.
225. Mehring J. Do Drugs Make a Dent? Bus Week 2004; 3877:32.
226. Meites J. Relation of the neuroendocrine system to the development and growth of experimental mammary tumors. J Neural Transm 1980; 48(1):25-42.
227. Melsen F, Melsen B, Mosekilde L, Bergmann S. Histomorpho-metric analysis of normal bone from the iliac crest. Acta Pathol Microbiol Scand 1978 86:70-81.
228. Micheli A, Muti P, Secreto G, Krogh V, Meneghini E, Venturelli E, Sieri S, Pala V, Berrino F. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 2004; 112(2):312-318.
229. Migeon CJ, Keller AR, Lawrence B, Shepart TH II. Dehydroepiandrosterone and androsterone levels in human plasma. Effect of age and sex: day-to-day and diurnal variations. J Clin Endocrinol Metab 1957; 17:1051-1062.
230. Miller WR, Stuart M, Sahmoud T, Dixon JM. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer. Br J Cancer 2002; 87(9):950-955.
231. Mistry P, Griffiths K, Maynard PV. Endogenous C19-steroids and estradiol levels in human primary breast tumor tissues and their correlation with androgen and estrogen receptors. J Steroid Biochem 1986; 24:1117-1125.
232. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78:1360-1367.
233. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the international letrozole breast cancer group. J Clin Oncol 2001; 19(10):2596-2606.
234. Murphy LC, Tsuyuki D, Myal Y, SHiu RPC. Isolation and sequencing of a cDNA clone for a prolactin-inducible protein (PIP). J Biol Chem 1987; 262:15236-15241.
235. Nair KS, Rizza RA, O'Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Dalla Man C, Tindall DJ, Melton LJ III, Smith GE, Khosla S, Jensen MD. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006; 355(16): 1647-1659.
236. Najid A, Habrioux G. Biological effects of adrenal androgens on MCF-7 and BT-20 human breast cancer cells. Oncology 1990; 47(3):269-274.
237. Najid A, Ratinaud MH. Comparative studies of steroidogenesis inhibitors (econazole, ketoconazole) on human breast cancer MCF-7 cell proliferation by growth experiments, thymidine incorporation and flow cytometric DNA analysis. Tumori 1991; 77(5):385-390.
238. Neri R, Peets E, Watnick A. Anti-androgenicity of flutamide and its metabolite Sch 16423. Biochem Soc Trans 1979; 7:565.
239. Onland-Moret NC, Kaaks R, van Noord PA, Rinaldi S, Key T, Grobbee DE, Peeters PH. Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer. Br J Cancer 2003; 88(9):1394-1399.
240. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984; 59:551-555.
241. Osborne CK, Coronado Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst; 1995. 87(10): 746-750.
242. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery A, Webster A, Morris R, Elledge R, Buzdar A. Double-blind, randomized trial comparing the efficacy and tolerability of Fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American Trial. J Clin Oncol 2002; 20(16):3386-3395.
243. Page JH, Colditz GA, Rifai N, Barbieri RL, Willett WC, Hankinson SE. Plasma adrenal androgens and risk of breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prev 2004; 13(6):1032-1036.
244. Parfitt AM. The cellular basis of bone remodeling: the quantum concept reexamined in light of recent advances in the cell biology of bone. Calcif Tissue Int 1984; 36(suppl 1): S37-S45.
245. Park JJ, Irvine RA, Buchanan G, Koh SS, Park JM, Tilley WD, Stallcup MR, Press MF, Coetzee GA. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res 2000; 60(21):5946-5949.
246. Pasqualini JR, Chetrite G, Blacker C, Feinstein MC, Delalonde L, Talbi M, Maloche C. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab 1996; 81(4): 1460-1464.
247. Pelletier G, Labrie C, Martel C, Labrie F. Chronic administration of dehydroepiandrosterone (DHEA) to female monkey and rat has no effect on mammary gland histology. J Steroid Biochem Mol Biol 2007 (in press).
248. Pelletier G, Luu-The V, El-Alfy M, Li S, Labrie F. Immunoelectron microscopic localization of 3b-hydroxysteroid dehydrogenase and type 5 17b-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J Mol Endocrinol 2001; 26(1):11-19.
249. Pelletier G, Luu-The V, Tetu B, Labrie F. Immunocytochemical localization of type 5 17b-hydroxysteroid dehydrogenase in human reproductive tissues. J Histochem Cytochem 1999; 47(6):731-737.
250. Perel E, Daniilescu D, Kharlip L, Blackstein ME, Killinger DW The relationship between growth and androstenedione metabolism in four cell lines of human breast carcinoma cells in culture. Mol Cell Endocrinol 1985; 41:197-203.
251. 10-metabolites in breast carcinoma, and benign prostatic hypertrophy tissue. J Steroid Biochem 1983; 19:1135-1139.
252. Peto R. Five years of tamoxifen-or more? J Natl Cancer Inst 1996; 88(24):1791-1793.
253. Peto R, Dalesio O. Breast and prostate cancer: 10-year survival gains in the hormonal adjuvant treatment trials. ECCO 12, Copenhagen. Eur J Cancer 2003 (abstr).
254. Picard F, Deshaies Y, Lalonde J, Samson P, Labrie C, Belanger A, Labrie F, Richard D. Effects of the estrogen antagonist EM-652. HCl on energy balance and lipid metabolism in ovariectomized rats. Int J Obes Relat Metab Disord 2000; 24(7):830-840.
255. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993; 15(1):17-35.
256. Poortman J, Thijssen JH, von Landeghem AA, Wiegerinck MA, Alsbach GP. Subcellular distribution of androgens and oestrogens in target tissue. J Steroid Biochem 1983; 19(1C): 939-945.
257. Poulin R, Baker D, Labrie F. Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treat 1988; 12:213-225.
258. Poulin R, Baker D, Poirier D, Labrie F. Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Breast Cancer Res Treat 1989a; 13:161-172.
259. 5-steroids in the ZR-75-1 human breast cancer cell line." Cancer Res 1986; 46: 4933-4937.
260. Poulin R, Mérand Y, Poirier D, Levesque C, Dufour JM, Labrie F. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen and ICI164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells. Breast Cancer Res Treat 1989b; 14:65-76.
261. Poulin R, Simard J, Labrie C, Petitclerc L, Dumont M, Lagace L, Labrie F. Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. Endocrinology 1989c; 125:392-399.
262. Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Dowsett M, McKinna JA, Nash AG, Sinnett HD. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 1989; 60(1):126-31.
263. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355:1491-1498.
264. Quadri SK, Kledzik GS, Meites J. Counteraction by prolactin of androgen-induced inhibition of mammary tumor growth in rats. J Natl Cancer Inst 1974; 52:875-878.
265. Ratko TA, Detrisac CJ, Mehta RG, Kelloff GJ, Moon RC. Inhibition of rat mammary gland chemical carcinogenesis by dietary dehydroepiandorsterone or a fluorinated analogue of dehydroepiandrosterone. Cancer Res 1991; 51(2):481-486.
266. Raynaud A. Fetal development of the mammary gland and hormonal effects on its morphogenesis. In: Falconer IR, ed. Lactation. University Park and London: Pennsylvania State University Press, 1971:1-29.
267. Recchione C, Ventrurelli E, Manzari A, Cavalleri A, Martinetti A, Secreto G. Testorterone, dihydrotestosterone and eostradiol levels in postmenopausal breast cancer tissue. J Steroid Biochem 1995; 52:541-546.
268. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Weiderpass E, Persson IR. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women J Natl Cancer Inst 2002; 94:497-504.
269. Rinaldi S, Key TJ, Peeters PH, Lahmann PH, Lukanova A, Dossus L, Biessy C, Vineis P, Sacerdote C, Berrino F, Panico S, Tumino R, Palli D, Nagel G, Linseisen J, Boeing H, Roddam A, Bingham S, Khaw KT, Chloptios J, Trichopoulou A, Trichopoulos D, Tehard B, Clavel-Chapelon F, Gonzalez CA, Larranaga N, Barricarte A, Quiros JR, Chirlaque MD, Martinez C, Monninkhof E, Grobbee DE, Bueno-de-Mesquita HB, Ferrari P, Slimani N, Riboli E, Kaaks R. Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: a study within the EPIC cohort. Int J Cancer 2006; 118(11):2832-2839.
270. Rochefort H, Garcia M. The estrogenic and antiestrogenic activities of androgens in female target tissues. Pharmacol Ther 1983; 23:193-216.
271. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2002; 285:1460-1465.
272. Roy J, Couillard S, Gutman M, Labrie F. A novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice. Breast Cancer Res Treat 2003; 81:223-229.
273. Roy R, Dauvois S, Labrie F, Belanger A. Estrogen-stimulated glucuronidation of dihydrotestosterone in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol 1992; 41:579-582.
274. Russo J, Russo IH. Biological and molecular bases of mammary carcinogenesis. Lab Invest 1987; 57:112-137.
275. Russo J, Russo IH. Morphology and development of the mammary gland. In: Jones TC, Morh U, Hunt R, eds. Monographs on Pathology of Laboratory Animals: Integument and Mammary Glands. New York: Springer-Verlag, 1989:233-252.
276. Russo J, Saby J, William MI, Russo IH. Pathogenesis of mammary carcinomas induced in rats by 7,12-dimethylbenz (a)anthracene. J Natl Cancer Inst 1977; 59:435-145.
277. Sato M, Turner CH, Wang T, Adrian MD, Rowley E, Bryant HU. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther 1998; 287:1-7.
278. Scatchard G. The attraction of proteins for small molecules and ions. Ann N Y Acad Sci 1959; 51:660-672.
279. Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 2005; 56(suppl 1):10-20.
280. Schwartz AG. Inhibition of spontaneous breast cancer formation in female C3H (Avy/a) mice by long-term treatment with dehydroepiandrosterone. Cancer Res 1979; 39:1129-1132.
281. Schwartz AG, Pashko L, Whitcomb JM. Inhibition of tumor development by dehydroepiandrosterone and related steroids. Toxicol Pathol 1986; 14:357-362.
282. Schwartz AG, Whitcomb JM, Nyce JW, Lewbart ML, Pashko LL. Dehydroepiandrosterone and structural analogs: a new class of cancer chemopreventive agents. Adv Cancer Res 1988; 51:391-424.
283. Secreto G, Toniolo P, Berrino F, Recchione C, Cavalleri A, Pisani P, Toris A, Fariselli G, Di Pietro S. Serum and urinary androgens and risk of breast cancer in potmeno-pausal women. Cancer Res 1991; 51:2572-2576.
284. Segaloff A. The use of androgens in the treatment of neoplastic disease. Pharm Ther 1977; C2:33-37.
285. Segaloff A, Gordon D, Horwitt BN, Schlosser JV, Murison PJ. Hormonal therapy in cancer of the breast. 1. The effect of testosterone propionate therapy on clinical course and hormonal excretion. Cancer 1951; 4:319-323.
286. Seymour-Munn K, Adams J. Estrogenic effects of 5-androstene-3 beta, 17 beta-diol at physiological concentrations and its possible implication in the etiology of breast cancer. Endocrinology 1983; 112(2):486-491.
287. Sherwin BB. Estrogen and cognitive functioning in women. Endocr Rev 2003; 24(2):133-151.
288. Simard J, Dauvois S, Haagensen DE, Levesque C, Merand Y, Labrie F. Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. Endocrinology 1990; 126:3223-3231.
289. Simard J, Hatton AC, Labrie C, Dauvois S, Zhao HF, Haagensen DE, Labrie F. Inhibitory effects of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells. Mol Endocrinol 1989; 3:694-702.
290. Simard J, Labrie C, Belanger A, Gauthier S, Singh SM, Merand Y, Labrie F. Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int J Cancer 1997a; 73:104-112.
291. Simard J, Luthy I, Guay J, Bélanger A, Labrie F. Characteristics of interaction of the antiandrogen Flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol 1986; 44:261-270.
292. Simard J, Sanchez R, Poirier D, Gauthier S, Singh SM, Merand Y, Belanger A, Labrie C, Labrie F. Blockade of the stimulatory effect of estrogens, OH-Tamoxifen, OH-Toremifene, Droloxifene and Raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res 1997b; 57:3494-3497.
293. Simoncini T, Fornari L, Mannella P, Varone G, Caruso A, Liao JK, Genazzani AR. Novel non-transcriptional mechanisms for estrogen receptor signaling in the cardiovascular system. Interaction of estrogen receptor alpha with phosphatidyli-nositol 3-OH kinase. Steroids 2002; 67(12):935-939.
294. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003; 86(3-5):225-230.
295. Somboonporn W, Davis SR. Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev 2004; 25(3):374-388.
296. Song D, Liu G, Luu-The V, Zhao D, Wang L, Zhang H, Xueling G, Li S, Desy L, Labrie F, Pelletier G. Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer. An immunocytochemical study. J Steroid Biochem Mol Biol 2006; 101(2-3):136-44.
297. Sourla A, Flamand M, Belanger A, Labrie F. Effect of dehydroepiandrosterone on vaginal and uterine histomorphology in the rat. J Steroid Biochem Mol Biol 1998a; 66(3):137-149.
298. Sourla A, Martel C, Labrie C, Labrie F. Almost exclusive androgenic action of dehydroepiandrosterone in the rat mammary gland. Endocrinology 1998b; 139:753-764.
299. Sturgeon SR, Potischman N, Malone KE, Dorgan JF, Daling J, Schairer C, Brinton LA Serum levels of sex hormones and breast cancer risk in premenopausal women: a case-control study (USA). Cancer Causes Control 2004; 15(1):45-53.
300. Swanson C, Lorentzon M, Vandenput L, Labrie F, Rane A, Jakobsson J, Chouinard S, Belanger A, Ohlsson C. Sex steroid levels and cortical bone size in young men are associated with a uridine diphosphate glucuronosyltransferase 2B7 polymorphism (H268Y). J Clin Endocrinol Metab 2007; 92:3697-3704.
301. Szymczak J, Milewicz A, Thijssen JH, Blankenstein MA, Daroszewski J. Concentration of sex steroids in adipose tissue after menopause. Steroids 1998; 63(5-6):319-21.
302. Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N, Lacroix I, Somma-Delpero C, Boudou P. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 2003; 49(8):1381-1395.
303. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 2006; 166(14):1483-1489.
304. Teller MN, Budinger JM, Zvilichovsky G, Watson AA, MdDonald JJ, Stohrer G, Brown GB. Oncogenicity of purine 3-oxide and unsubstituted purine in rats. Cancer Res 1978; 38:2229-2232.
305. Thériault C, Labrie F. Hormonal regulation of estradiol 17b-hydroxysteroid dehydrogenase activity in the ZR-75-1 human breast cancer cell line. Ann N Y Acad Sci 1990; 595:419-421.
306. Thijssen JH, Blankenstein MA, Donker GH, Daroszewski J. Endogenous steroid hormones and local aromatase activity in the breast. J Steroid Biochem Mol Biol 1991; 39 (5B):799-804.
307. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, Wang DY. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer 1997; 76(3):401-405.
308. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P, Pasternack BS. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995; 87(3):190-197.
309. Tormey DC, Lippman ME, Edwards BK, Cassidy JG. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med 1983; 98:139-144.
310. Toth-Fejel S, Cheek J, Calhoun K, Muller P, Pommier RF. Estrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic tool. Arch Surg 2004; 139(1):50-54.
311. Tralongo P, Di Mari A, Ferrau F. Cognitive impairment, aro-matase inhibitors, and age. J Clin Oncol 2005; 23(18):4243.
312. Tworoger SS, Missmer SA, Eliassen AH, Spiegelman D, Folkerd E, Dowsett M, Barbieri RL, Hankinson SE. The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev 2006; 15(5):967-71.
313. Ulrich P. Testosterone (hormone mAle) et son role possible dans le traitement de certains cancers du sein. Acta Unio Int Contra Cancrum 1939; 377-379.
314. Vakamatsou EH, Villanueva A, Stanciu J, Sudhaker RD, Parfitt AM. Calcif Tissue Int 1985, 37:594-597.
315. Van Landedgem AA, Poortman J, Nabuurs M, Thijssen JHH. Endogenous concentrations and subcellular distribution of estrogens in normal and malignant human breast cancer tissues. Cancer Res 1985; 45:2900-2906.
316. Van Uytfanghe K, Stockl D, Kaufman JM, Fiers T, Ross HA, De Leenheer AP, Thienpont LM. Evaluation of a candidate reference measurement procedure for serum free testosterone based on ultrafiltration and isotope dilution-gas chromatography-mass spectrometry. Clin Chem 2004; 50(11): 2101-2110.
317. Vandenput L, Labrie F, Mellstrom D, Swanson C, Knutsson T, Peeker R, Ljunggren O, Orwoll E, Eriksson AL, Damber JE, Ohlsson C. Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. J Bone Miner Res 2007; 22(2):220-227.
318. Vermeulen A, Deslypere JP, Paridaens R. Steroid dynamics in the normal and carcinomatous mammary gland. J Steroid Biochem 1986a; 25(5B):799-802.
319. Vermeulen A, Deslypere JP, Paridaens R, Leclercq G, Roy F, Heuson JC. Aromatase, 17b-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 1986b; 22:515-525.
320. Vermeulen A, Deslypene JP, Schelfhout W, Verdonck L, Rubens R. Adrenocortical function in old age: response to acute adrenocorticotropin stimulation. J Clin Endocrinol Metab 1982; 54:187-191.
321. Vermeulen A, Verdonck L. Radioimmunoassays of 17b-hydroxy-5a-androstan-3-one, 4-androstene-3,17-dione, dehydroepiandrosterone, 17b-hydroxyprogesterone and progesterone and its application to human male plasma. J Steroid Biochem 1976; 7:1-10.
322. Vermeulen A, Verdonck L. Factors affecting sex hormone levels in postmenopausal women. J Steroid Biochem 1979; 11:899-904.
323. Vogel VG, Costantino JP, Wickerham DL, Cronin WM. Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 2002; 94(19):1504.
324. Von Schoultz B. Androgens and the breast. Maturitas doi:10.1016/j.maturitas.2007.02.012.
325. Wakeling AE, Bowler J. Biology and mode of action of pure antiestrogens. J Steroid Biochem 1988; 30:141-147.
326. Wang DY, Allen DS, De Stavola BL, Fentiman IS, Brussen J, Bulbrook RD, Thomas BS, Hayward JL, Reed MJ. Urinary androgens and breast cancer risk: results from a long-term prospective study based in Guernsey. Br J Cancer 2000; 82(9):1577-1584.
327. Weinstein RS, Hutson MS. Decreased trabecular width and increased trabecular spacing contribute to bone loss with aging. Bone 1987; 8:137-142.
328. Wickerham DL, Fourchotte V. An update on breast cancer prevention trials. Int J Gynecol Cancer 2006; 16 (suppl 2): 498-501.
329. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W, Santoro N. Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2006; 91(10):3697-710.
330. Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288:321-333.
331. Wysowski DK, Honig SF, Beitz J. Uterine sarcoma associated with tamoxifen use. N Engl J Med 2002; 346(23):1832-1833.
332. Yaffe K. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998; 279: 688-695.
333. Yeh S, Hu YC, Rahman M, Lin HK, Hsu CL, Ting HJ, Kang HY, Chang C. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc Natl Acad Sci USA 2000; 97(21):11256-11261.
334. Young SR, Baker A, Helfestein JE. The effects of androgens on induced mammary tumors in rats. Br J Cancer 1965; 19:155-159.
335. Zava DT, McGuire WL. Estrogen receptors in androgen-induced breast tumor regression. Cancer Res 1977; 37(6):1608-1610.
336. Zava DT, McGuire WL. Human breast cancer: androgen action mediated by estrogen receptor. Science 1978; 199(4330): 787-788.
337. Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. Faseb J 2000; 14(12):1725-1730.